Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8784335 | 0.95 | CYP1A2 (0.82) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8783422 | 0.92 | KDM4E (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8783900 | 0.92 | CYP1A2 (0.84) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL1998890 | 0.91 | CYP1A2 (1.00) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL29457697 | 0.91 | CYP1A2 (1.00) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL29580184 | 0.91 | CYP1A2 (1.00) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784076 | 0.88 | CYP1A2 (0.77) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784597 | 0.86 | CYP1A2 (0.74) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8069028 | 0.86 | CYP1A2 (0.74) | CYP1A2KDM4EMEN1CYP2D6CYP2C19 | |
| SCHEMBL8784053 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0481676-B1 | Hydroxyquinolone derivatives | MERCK SHARP & DOHME (GB) | 1997-01-29 | — | — | EP | claimed |
| US-5348962-A | Nervous system disorders; schizophrenia | MERCK SHARPE & DOHME LTD. | 1994-09-20 | — | — | US | claimed |
| EP-0481676-A1 | Hydroxyquinolone derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-04-22 | — | — | EP | claimed |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| EP-0481676-B1 | Hydroxyquinolone derivatives | MERCK SHARP & DOHME (GB) | 1997-01-29 | — | — | EP | disclosed |
| US-5559125-A | NMDA AND AMPA RECEPTOR ANTAGONISTS, SCHIZOPHRENIA | MERCK, SHARP & DOHME LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| US-5348962-A | Nervous system disorders; schizophrenia | MERCK SHARPE & DOHME LTD. | 1994-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | GRIN1, GRIN2A, GRIN3A | CYP1A2 4176/4885KDM4E 1948/4885MEN1 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.